continuous glucose monitoring in europe: revolutionizing diabetes care
TRANSCRIPT
Continuous Glucose Monitoring in Europe: Revolutionizing Diabetes Care
Akanksha Joshi, Senior Research AnalystHealthcare
April 22, 2010
2
Agenda
• Diabetes – A growing concern
• Glucose monitoring
• Continuous Glucose Monitoring
• Market Trends – Growth factors, Restraints
• Market Potential
• Key Focus Points
3
Diabetes – A Growing Concern
As per the International Diabetes Federation, in 2010, the adult population with diabetes is likely to reach 55.2 million in Europe and around 285 million people worldwide will live with diabetes in the same year.
Also the national prevalence rate of diabetes varies from country to country in Europe – 2.1 per cent in Iceland to 12.0 per cent in Germany.
The IDF further indicates that in 2010 the healthcare expenditure on diabetes is likely to be US$ 106 billion in the European region a share of 28 per cent of the global expenditure.
Further it is estimated that 630,000 people would succumb to death due to diabetes in 2010. This number accounts for 11 per cent of deaths in the age group of 20-79.
Source: IDF Diabetes Atlas fourth edition
4
Prevalence percent of Diabetes
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
Pe
r c
en
t o
f p
op
ula
tion
Belgium Denmark Finland France Germany Italy LuxembourgNetherlands Norway Spain Sweden United
Kingdom
Country
2009 2012
Germany is the biggest market owing
to the largest diabetic population in
Europe. The diabetic population is
expected to be 7.5 million in 2010.
Source: Frost & Sullivan
5
Glucose Monitoring
An Overview An Overview
•The traditional method of monitoring glucose involves sticking fingerstick to gain access to
glucose. The inconvenience associated with this method makes it difficult for the patient to
maintain tight glycemic level because of the inconvenience involved.
• Episodic monitoring of glucose does not provide information about changes in level of
glucose between two consecutive measurements. Unawareness regarding a patient falling
or rising glycemic level could lead to serious medical condition.
•Continuous Glucose monitoring is of help for patients who have vast fluctuations in their
glycemic level. Using this method the treatment plan of a diabetic can be well adjusted all
through the day. The method also relieves the patient of sticking finger stick and getting rid
of the discomfort caused.
•The traditional method of monitoring glucose involves sticking fingerstick to gain access to
glucose. The inconvenience associated with this method makes it difficult for the patient to
maintain tight glycemic level because of the inconvenience involved.
• Episodic monitoring of glucose does not provide information about changes in level of
glucose between two consecutive measurements. Unawareness regarding a patient falling
or rising glycemic level could lead to serious medical condition.
•Continuous Glucose monitoring is of help for patients who have vast fluctuations in their
glycemic level. Using this method the treatment plan of a diabetic can be well adjusted all
through the day. The method also relieves the patient of sticking finger stick and getting rid
of the discomfort caused.
6
Continuous Glucose Monitoring
A step ahead ..A step ahead ..
•A continuous glucose monitor uses a sensor and transmitter attached to the body that
communicate with a handheld receiver or an insulin pump.
•The calibration of CGM is based on the standard meter. The average number of calibrations
would be two fingertip blood glucose test per 24 hours. Calibrating the CGM on a regular
basis is a must for accurate readings.
•CGM measure glucose in the interstitial fluid so the lag effect seems to be evident when
compared to traditional blood glucose level. CGM is advantageous and accurate as the
glucose level rises in the blood first and then increases in the interstitial fluid.
•A continuous glucose monitor uses a sensor and transmitter attached to the body that
communicate with a handheld receiver or an insulin pump.
•The calibration of CGM is based on the standard meter. The average number of calibrations
would be two fingertip blood glucose test per 24 hours. Calibrating the CGM on a regular
basis is a must for accurate readings.
•CGM measure glucose in the interstitial fluid so the lag effect seems to be evident when
compared to traditional blood glucose level. CGM is advantageous and accurate as the
glucose level rises in the blood first and then increases in the interstitial fluid.
7
Continuous Glucose Monitoring – different technologies involved
Minimally
Invasive
Non – Invasive
Implantable Based on the
Technology
The sensor is placed in the body for minimum period of 6 months to a year. This technology involves a threat from infections during the placement and replacement of sensors. Major issue concerning the research and development team in regards to this technique is the biocompatibility of the sensor.
This technology involves a small
incision in to the body to acquire
blood or Interstitial Fluid (ISF)
through micro channels on the
skin surface. The replacement
period of these sensors varies
from 3 days to 5 days to a
maximum of 7 days. The patient
comfort level is quite low in
treatment for this method.
This technology incorporates optical
methods and the sensor placement
depends on the usage. The accuracy
involved in this approach is debatable
and depends on the size and the optical
method used.
Source: Frost & Sullivan
8
In the competition
Company Products
Medtronic Inc. MiniMed Paradigm® Veo™ System
Guardian REAL-Time Continuous
Glucose Monitoring System
Abbott Laboratories Abbott FreeStyle Navigator®
DexCom Inc SEVEN® PLUS
A. Menarini GlucoDay®SSource: Frost & Sullivan
9
Integration of insulin pump with the monitoring devices
Awareness regarding diabetes among the people as well as government organisation
Increase in requirement of glucose monitoring devices
Ease of use and better patient comfort likely to spur market growth
Growth Factors: Revolutionising the Market space
Source: Frost & Sullivan
10
Roadblocks for the revolution in the CGM Industry
Reimbursement of the device
Clinically benchmarked and affordable technologies available in the market
Lack of awareness and fear of new technology
Reliance on Physicianfor adopting the
technology
Source: Frost & Sullivan
11
Market Potential – Glucose Monitoring
....
....
• Market Potential For Blood Glucose Monitoring
• Traditional Blood Glucose Monitors Market
• CGM Market
Total
CGM
Total
SBGM
Market
Potential
Revenue 2009
Per
cent
gro
wth
If the concerns regarding reimbursement
are resolved the CGM market would be
seen replacing the self blood glucose
monitoring market.
The continuous glucose
monitoring market in Europe
has seen increased penetration
in recent times. Competitive
analysis suggests that with the
entry of new market
participants, the dynamics of
the market would change in
2010.
Source : Frost & Sullivan
12
Key Focus Points
Source: Frost & Sullivan
Strategic Alliances� Strategic Alliances
� Clinicians Support
� Cost Benefit Evidence
13
Next Steps
� Request a strategic approach document for a Growth Partnership Service or Growth Consulting Service to support you and your team to accelerate the growth of your company.
([email protected]) +44 (0)20 7343 8383
� Join us at our annual Growth, Innovation and Leadership 2010: A Frost & Sullivan Global Congress on Corporate Growth London, United Kingdom
(www.gil-global.com)
� Register for the next Chairman’s Series on Growth:
M&A - Identifying Stealth Opportunities Beneath Your Radar & Other Best Practices
12 May 2010 10:00 AM BST (www.frost.com/growthEU)
� Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities (www.frost.com/news)
14
Your Feedback is Important to Us
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by taking our survey.
What would you like to see from Frost & Sullivan?
15
Find us @Frost_Sullivan on Twitter
Frost & Sullivan on Twitter and Facebook
Become a fan of Frost & Sullivan on Facebook
16
For Additional Information
Katja Feick
Corporate Communications
Healthcare
0049 (0) 69 7703343
Noel Anderson
European Vice President
New Business Development
+44 (0)207 343 8389
Siddharth Saha
Director of Research
Healthcare
+ 44 (0) 207 343 8374